Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (10465)	2/17/2004 5:48:13 PM
From: Miljenko Zuanic	Respond to of 52153

What a depressed report from depressed country! You are what you eat and how you feel? <<"The proton pump inhibitors (anti-ulcerants) and the SSRI/SNRI (antidepressants), the number 2 and 3 classes respectively, held their market positions last year even though consumers had the choice of a generic substitute(s) in both classes, along with the additional competition of an OTC anti-ulcerant, AstraZeneca's Prilosec OTC(TM)," remarked Doug Long, vice president of IMS Industry Relations. "The antihistamine (allergy) class slipped to ninth position from seventh the prior year due to OTC competition from Schering-Plough's Claritin(R) OTC.">>

To: Icebrg who wrote (10465)	2/17/2004 6:14:50 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

Putting on my cost-cutting hat, I note over $7 billion of payments for Prevacid and Nexium. The reality is that neither of these are significantly better than generic Prilosec. (The Nexium "improvement" was largely because they compared the new drug to the label dose of Prilosec (20mg) rather than the more potent 40mg dosage form.) So I contend we could instantly cut $6 billion out of health care costs without significantly hurting the consumer. Peter